2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen A, Sharon E, O'Sullivan-Coyne G, Moore N, Foster J, Hu J, Van Tine B, Conley A, Read W, Riedel R, Burgess M, Glod J, Davis E, Merriam P, Naqash A, Fino K, Miller B, Wilsker D, Begum A, Ferry-Galow K, Deshpande H, Schwartz G, Ladle B, Okuno S, Beck J, Chen J, Takebe N, Fogli L, Rosenberger C, Parchment R, Doroshow J. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal Of Medicine 2023, 389: 911-921. PMID: 37672694, PMCID: PMC10729808, DOI: 10.1056/nejmoa2303383.Peer-Reviewed Original ResearchConceptsAdvanced alveolar soft part sarcomaAlveolar soft part sarcomaProgression-free survivalSoft part sarcomaObjective responsePart sarcomaMedian progression-free survivalTreatment-related grade 4Rare soft tissue sarcomaData cutoff dateImmune checkpoint inhibitorsPhase 2 studyResponse Evaluation CriteriaThird of patientsDuration of responseSoft tissue sarcomasYears of treatmentCheckpoint inhibitorsAdverse eventsMedian durationPartial responseComplete responseDeath-1PD-L1Pediatric patients
2022
Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel C, Deshpande H, Patwa H, Peixoto A. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 2022, 15: e247140. PMID: 36549761, PMCID: PMC9791444, DOI: 10.1136/bcr-2021-247140.Peer-Reviewed Original ResearchConceptsOrthostatic hypotensionVascular endothelial growth factor inhibitorsLower extremity weaknessNeurogenic orthostatic hypotensionPalpable abdominal massGrowth factor inhibitorsHistory of fatigueAppropriate chronotropic responseSupine hypertensionAbdominal painAutonomic testingExtremity weaknessAbdominal massSodium intakeChronotropic responseFactor inhibitorsCompression stockingsDesmoid tumorsLiberal fluidsSympathetic responseHypotensionTumor growthSorafenibGradual improvementTreatmentAssociation Between Postdischarge Medical Oncology Follow-Up Appointments and Downstream Health Care Use: A Single-Institution Experience
Xiang J, Chow R, Reynoso A, Carafeno T, Deshpande H, Strait M, Prsic E. Association Between Postdischarge Medical Oncology Follow-Up Appointments and Downstream Health Care Use: A Single-Institution Experience. JCO Oncology Practice 2022, 18: e1466-e1474. PMID: 35696632, DOI: 10.1200/op.21.00868.Peer-Reviewed Original ResearchConceptsHealth care useED visitsCare useOncology appointmentsAppointment timingPropensity score-matched analysisMultivariable logistic regression modelYale-New Haven HospitalRetrospective cohort studySingle institution experienceEmergency department visitsTertiary academic centerNew Haven HospitalLower ratesLogistic regression modelsOncology admissionsOncology followCause readmissionMost admissionsCohort studyDepartment visitsMedical oncologySubgroup analysisReadmissionAcademic centersEfficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent groupSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Morales C, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal Of Clinical Oncology 2022, 40: 2479-2490. PMID: 35394800, PMCID: PMC9467680, DOI: 10.1200/jco.21.01829.Peer-Reviewed Original ResearchConceptsProgression-free survivalDedifferentiated liposarcomaNext treatmentCommon treatment-emergent adverse eventsPatients age 12 yearsTreatment-emergent adverse eventsLonger progression-free survivalPlacebo-controlled studyPrimary end pointLines of therapyAge 12 yearsAdverse eventsOverall survivalPlacebo armSupportive careClinical benefitStudy treatmentPredictive biomarkersPreclinical modelsProspective validationGrade 3Dose reductionPlaceboSide effectsPatients
2018
An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E, Deshpande H, Stein S. An update of lanreotide acetate for treatment of adults with carcinoid syndrome. Drugs Of Today 2018, 54: 457-465. PMID: 30209440, DOI: 10.1358/dot.2018.54.8.2834461.Peer-Reviewed Original ResearchConceptsSymptoms of carcinoid syndromeCarcinoid syndromeCarcinoid tumorsOrigin of carcinoid tumorsTreatment of carcinoid syndromeUrinary 5-hydroxyindoleacetic acidAdvanced metastatic diseaseSomatostatin analogue octreotideTreatment of adultsMetastatic diseaseSerotonin metaboliteAnalogue octreotideNative somatostatinDebilitating diarrheaLanreotide acetateSyndromeTumorSymptom controlLanreotideSlow-growingSymptomsSomatostatinTreatmentHalf-lifeChemotherapy